166 related articles for article (PubMed ID: 36264865)
1. Molecular and clinicopathological differences between depressed and protruded T2 colorectal cancer.
Mochizuki K; Kudo SE; Kato K; Kudo K; Ogawa Y; Kouyama Y; Takashina Y; Ichimasa K; Tobo T; Toshima T; Hisamatsu Y; Yonemura Y; Masuda T; Miyachi H; Ishida F; Nemoto T; Mimori K
PLoS One; 2022; 17(10):e0273566. PubMed ID: 36264865
[TBL] [Abstract][Full Text] [Related]
2. Consensus molecular subtype classification of colorectal adenomas.
Komor MA; Bosch LJ; Bounova G; Bolijn AS; Delis-van Diemen PM; Rausch C; Hoogstrate Y; Stubbs AP; de Jong M; Jenster G; van Grieken NC; Carvalho B; Wessels LF; Jimenez CR; Fijneman RJ; Meijer GA;
J Pathol; 2018 Nov; 246(3):266-276. PubMed ID: 29968252
[TBL] [Abstract][Full Text] [Related]
3. A modified protein marker panel to identify four consensus molecular subtypes in colorectal cancer using immunohistochemistry.
Li X; Larsson P; Ljuslinder I; Ling A; Löfgren-Burström A; Zingmark C; Edin S; Palmqvist R
Pathol Res Pract; 2021 Apr; 220():153379. PubMed ID: 33721619
[TBL] [Abstract][Full Text] [Related]
4. Immunohistochemistry-Based Consensus Molecular Subtypes as a Prognostic and Predictive Biomarker for Adjuvant Chemotherapy in Patients with Stage II Colorectal Cancer.
Li Y; Yao Q; Zhang L; Mo S; Cai S; Huang D; Peng J
Oncologist; 2020 Dec; 25(12):e1968-e1979. PubMed ID: 32926498
[TBL] [Abstract][Full Text] [Related]
5. Microenvironment, systemic inflammatory response and tumor markers considering consensus molecular subtypes of colorectal cancer.
Jakab A; Patai ÁV; Darvas M; Tormássi-Bély K; Micsik T
Pathol Oncol Res; 2024; 30():1611574. PubMed ID: 38645565
[No Abstract] [Full Text] [Related]
6. Association of Consensus Molecular Subtypes and Molecular Markers With Clinical Outcomes in Patients With Metastatic Colorectal Cancer: Biomarker Analyses From LUME-Colon 1.
Lenz HJ; Argiles G; Yoshino T; Tejpar S; Ciardiello F; Braunger J; Salnikov AV; Gabrielyan O; Schmid R; Höfler J; Kitzing T; Van Cutsem E
Clin Colorectal Cancer; 2021 Mar; 20(1):84-95.e8. PubMed ID: 33041226
[TBL] [Abstract][Full Text] [Related]
7. The prognostic impact of consensus molecular subtypes (CMS) and its predictive effects for bevacizumab benefit in metastatic colorectal cancer: molecular analysis of the AGITG MAX clinical trial.
Mooi JK; Wirapati P; Asher R; Lee CK; Savas P; Price TJ; Townsend A; Hardingham J; Buchanan D; Williams D; Tejpar S; Mariadason JM; Tebbutt NC
Ann Oncol; 2018 Nov; 29(11):2240-2246. PubMed ID: 30247524
[TBL] [Abstract][Full Text] [Related]
8. Clinical Value of Consensus Molecular Subtypes in Colorectal Cancer: A Systematic Review and Meta-Analysis.
Ten Hoorn S; de Back TR; Sommeijer DW; Vermeulen L
J Natl Cancer Inst; 2022 Apr; 114(4):503-516. PubMed ID: 34077519
[TBL] [Abstract][Full Text] [Related]
9. Phenotypic subtypes predict outcomes in colorectal cancer.
Kasurinen J; Beilmann-Lehtonen I; Kaprio T; Hagström J; Haglund C; Böckelman C
Acta Oncol; 2023 Mar; 62(3):245-252. PubMed ID: 36867078
[TBL] [Abstract][Full Text] [Related]
10. Associations of non-pedunculated T1 colorectal adenocarcinoma outcome with consensus molecular subtypes, immunoscore, and microsatellite status: a multicenter case-cohort study.
Haasnoot KJC; Backes Y; Moons LMG; Kranenburg O; Trinh A; Vermeulen L; Noë M; Tuynman JB; van Lent AUG; van Ginneken R; Seldenrijk CA; Raicu MG; Trumpi K; Ubink I; Milne AN; Boonstra JJ; Groen JN; Schwartz MP; Wolfhagen FHJ; Geesing JMJ; Ter Borg F; Brosens LAA; van Bergeijk J; Spanier BWM; de Vos Tot Nederveen Cappel WH; Kessels K; Seerden TCJ; Vleggaar FP; Offerhaus GJA; Siersema PD; Elias SG; Laclé MM;
Mod Pathol; 2020 Dec; 33(12):2626-2636. PubMed ID: 32581367
[TBL] [Abstract][Full Text] [Related]
11. Classification of patients with metastatic colorectal cancer into consensus molecular subtypes into real-world: A pilot study.
González-Montero J; Burotto M; Valenzuela G; Mateluna D; Buen-Abad F; Toro J; Barajas O; Marcelain K
World J Clin Oncol; 2023 Oct; 14(10):409-419. PubMed ID: 37970108
[TBL] [Abstract][Full Text] [Related]
12. [Characterization of patients with sporadic colorectal cancer following the new Consensus Molecular Subtypes (CMS)].
Wielandt AM; Villarroel C; Hurtado C; Simian D; Zamorano D; Martínez M; Castro M; Vial MT; Kronberg U; López-Kostner F
Rev Med Chil; 2017 Apr; 145(4):419-430. PubMed ID: 28748988
[TBL] [Abstract][Full Text] [Related]
13. The Evolving Role of Consensus Molecular Subtypes: a Step Beyond Inpatient Selection for Treatment of Colorectal Cancer.
Ros J; Baraibar I; Martini G; Salvà F; Saoudi N; Cuadra-Urteaga JL; Dienstmann R; Tabernero J; Élez E
Curr Treat Options Oncol; 2021 Nov; 22(12):113. PubMed ID: 34741675
[TBL] [Abstract][Full Text] [Related]
14. Colorectal Cancer Consensus Molecular Subtypes Translated to Preclinical Models Uncover Potentially Targetable Cancer Cell Dependencies.
Sveen A; Bruun J; Eide PW; Eilertsen IA; Ramirez L; Murumägi A; Arjama M; Danielsen SA; Kryeziu K; Elez E; Tabernero J; Guinney J; Palmer HG; Nesbakken A; Kallioniemi O; Dienstmann R; Lothe RA
Clin Cancer Res; 2018 Feb; 24(4):794-806. PubMed ID: 29242316
[No Abstract] [Full Text] [Related]
15. Image-based assessment of extracellular mucin-to-tumor area predicts consensus molecular subtypes (CMS) in colorectal cancer.
Nguyen HG; Lundström O; Blank A; Dawson H; Lugli A; Anisimova M; Zlobec I
Mod Pathol; 2022 Feb; 35(2):240-248. PubMed ID: 34475526
[TBL] [Abstract][Full Text] [Related]
16. Detection of postoperative plasma circulating tumour DNA and lack of CDX2 expression as markers of recurrence in patients with localised colon cancer.
Tarazona N; Gimeno-Valiente F; Gambardella V; Huerta M; Roselló S; Zuniga S; Calon A; Carbonell-Asins JA; Fontana E; Martinez-Ciarpaglini C; Eason K; Rentero-Garrido P; Fleitas T; Papaccio F; Moro-Valdezate D; Nyamundanda G; Castillo J; Espí A; Sadanandam A; Roda D; Cervantes A
ESMO Open; 2020 Sep; 5(5):e000847. PubMed ID: 32967918
[TBL] [Abstract][Full Text] [Related]
17. Consensus molecular subtypes (CMS) in metastatic colorectal cancer - personalized medicine decision.
Rebersek M
Radiol Oncol; 2020 May; 54(3):272-277. PubMed ID: 32463385
[TBL] [Abstract][Full Text] [Related]
18. Simple classifiers for molecular subtypes of colorectal cancer.
Kim WG; Kim JY; Park DY
Arab J Gastroenterol; 2017 Dec; 18(4):191-200. PubMed ID: 29241727
[TBL] [Abstract][Full Text] [Related]
19. Clinicopathological features of nonpolypoid colorectal tumors as viewed from the patients' background.
Abe S; Terai T; Sakamoto N; Beppu K; Nagahara A; Kobayashi O; Ohkusa T; Ogihara T; Hirai S; Kamano T; Miwa H; Sato N
J Gastroenterol; 2006 Apr; 41(4):325-31. PubMed ID: 16741611
[TBL] [Abstract][Full Text] [Related]
20. CDX2 prognostic value in stage II/III resected colon cancer is related to CMS classification.
Pilati C; Taieb J; Balogoun R; Marisa L; de Reyniès A; Laurent-Puig P
Ann Oncol; 2017 May; 28(5):1032-1035. PubMed ID: 28328000
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]